Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting

View Full Paper
Ask AI
Bookmark
Share

Authors

GFGabriela ForestieriXSXenia SchmidtTNThomas Noesslinger

Discussion

Loading...

Member takes

Overview

Analysis shows venetoclax treatment achieves low drug resistance rates in CLL, indicating improved progression-free survival.

Key Points

  • uMRD rates of 58% by MFC and 67% by CAPP-seq indicate effective venetoclax treatment.
  • Twelve patients in this cohort showed 63.1% complete remission after 24 months of therapy.
  • Analysis of peripheral blood samples tracked clonal evolution and drug resistance during treatment.
  • This study suggests that venetoclax-based regimens may offer improved progression-free survival in CLL cases.

Cite This Study

Forestieri et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1afhttps://doi.org/10.1182/blood-2025-3901
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia2025 · 1 citations
  2. 2Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study2025 · 1 citations
  3. 3Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  4. 4Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis2025
  5. 5Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial2025